31 biopharmaceutical companies are now involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. This article tracks the performance of 15 of them in the munKNEE Psychedelic Stocks Index.

[TM Editors Note: Many of the companies mentioned in this article are penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.]

Index Inclusion Criteria

• a market capitalization between US$10M and US$200M
• a stock that trades between US$0.10/share and US$2/share

Below are the 15 eligible companies in the munKNEE Psychedelic Stocks Index and their performance for the week ended December 18th. The previous week's performance is in brackets. To avoid duplication please refer to a previous article (see here) in which I provided introductory paragraphs on each of the above constituents.

1. Better Plant (VEGGF) +N/C (+83.3%) 
2. Champignon (SHRMF) -2.5%  (+76.1%)
3. Cybin (CLXPF) +39.4% (+34.7%)
4. Havn (HAVLF) +15.6% (+22.2%)
5. Hollister (HSTRF) +29.4% (+41.7%) 
6. Jaguar (JAGX) No Change (N/C)
7. Mind Cure (MCURF) -5.7% (+29.6%) 
8. Mydecine (MYCOF) +13.9% (+63.6%)
9. Nova Mentis (LIBFF) -20.0% (N/C)
10. Numinus (LKYSF) +23.7% (+86.9%)
11. Psyched Wellness (DCNPF) +3.7% (+28.5%)
12. Red Light (TRUFF) +42.1%  (+111.1%)
13. Revive (RVVTF) +29.3% (+78.2%)
14. Seelos (SEEL) +37.6% (+7.9%)
15. Silo Pharma (SILO) +11.6 (N/C)

The average performance of the above 15 psychedelic drug stocks last week was +18.7% compared to +35.3% the previous week.

NOTE: The 3 largest psychedelic drug stocks in the sector are not included in the Index because they either trade in excess of $2/share and/or have a market cap in excess of $200M as their inclusions would make a comparative analysis and Index averages meaningless. For the record, below are their performances this past week with a reference to their performance the week before that (in brackets), as follows:

1. Field Trip (FTRPF) +12.0% (+29.9%)
2. MindMed (MMEDF) +1.4% (+90.5%)
3. Compass (CMPS) -0.07% (+18.1%)

The remaining 13 stocks in this fledgling, yet burgeoning, sector were up 7.8% for the week. They are not eligible for inclusion in the munKNEE Psychedelic Stocks Index but are worth watching closely (see a previous article on the subject here) with the sector starting to gain considerable traction. They are as follows:

• Aion (CNSX:AION), Codebase (BKLLF), Ehave (EHVVF), Graph Blockchain (REGRF), Lobe Sciences (GTSIF), New Wave (TRMNF), Thoughtful Brands (PEMTF), Entheon (ENBI), Core One (CLABF), Newscope-PharmaTher (PHRM) and Nutritional High (SPLIF), Pure Extracts (PULL) and Tryp Therapeutics (TRYP).

Please note that Minerco (MINE) has been removed from the list as it is trading below $0.01/share on very spotty volume and Tryp Therapeutics (CSE:TRYP), which was just listed on Friday, has been added.